Patient advocacy groups can play a pivotal role in the successful development and launch of rare disease therapies. Early collaboration with patient advocacy groups can be a critical determinant of launch success. How can launch excellence teams ensure patient perspectives are meaningfully embedded throughout the drug development lifecycle?
• Building strong relationships with patients, caregivers, patient advocacy groups and external experts to maximise the success of your rare disease therapy launch
• Leveraging patient advocacy group partnerships to gain critical insights, engage diverse patient populations and support market access efforts to ensure your therapy successfully reaches patients who need it most
• Discovering how successful rare disease launches benefited from strong collaboration with patient advocacy groups to apply lessons learned to your next launch
Check out the incredible speaker line-up to see who will be joining Philipp.
The browser you are using is not supported that will prevent you from accessing certain features of the website. We want you to have the best possible experience. For this you'll need to use a supported browser and upgrade to the latest version.